Skip to search formSkip to main contentSkip to account menu

MKC-1

An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites… 
National Institutes of Health

Related topics

Related topics

2 relations
Microtubule ProcessR440

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and… 
2016
2016
The Developtment of Creative Writing Model on Short Story Based Siri’ Na Pacce at the XI Class Senior High Schools in Makassar
The research was a development model in teaching of creative writing short story based siri’na pace. The purpose of this study… 
2010
2010
Phase I study of continuous MKC-1 (cMKC-1) in patients (pts) with advanced or metastatic solid malignancies using a modified time-to-event continual reassessment method (TITE-CRM) for dose assignment…
e13001 Background: MKC-1 is an oral cell-cycle inhibitor amenable to a variety of dosing schedules. Previous clinical trials used… 
2009
2009
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi… 
2009
2009
Abstract #5353: MKC-1 interacts with multiple protein targets: Characterization by induced fluorescence
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO MKC-1 is a clinical-stage orally active cell-cycle inhibitor that exhibits… 
2008
2008
A phase II study of oral MKC-1 for metastatic breast cancer (MBC)
1046 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… 
2008
2008
Phase 1/2 trial of MKC-1 and pemetrexed in patients (pts) with advanced NSCLC
19052 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… 
2007
2007
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity… 
2007
2007
MKC-1 significantly increases survival of mice bearing renal cell carcinoma Caki-1 xenograft tumors through inhibition of the Akt/mTOR pathway
B290 MKC-1 (previously Ro 31-7453) is a novel, orally active cell cycle inhibitor with significant in vitro and in vivo activity… 
2006
2006
MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.
MKC-1 is a novel, orally active cell cycle inhibitor with in vitro and in vivo activity against a wide range of human solid tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)